AbbVie Inc  

(Public, NYSE:ABBV)   Watch this stock  
Find more results for ABBV
73.91
-0.70 (-0.94%)
Pre-market: 74.00 +0.09 (0.12%)
Jul 25, 4:03AM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 73.84 - 74.75
52 week 55.06 - 75.04
Open 74.63
Vol / Avg. 700.00/5.21M
Mkt cap 118.62B
P/E 19.03
Div/yield 0.64/3.46
EPS 3.88
Shares 1.59B
Beta 1.52
Inst. own 70%
Jul 28, 2017
Q2 2017 AbbVie Inc Earnings Release - 9:30AM EDT - Add to calendar
Jul 28, 2017
Q2 2017 AbbVie Inc Earnings Call - 9:00AM EDT - Add to calendar
Jun 13, 2017
AbbVie Inc at Goldman Sachs Global Healthcare Conference - Webcast
Jun 8, 2017
AbbVie Inc at Jefferies Healthcare Conference - Webcast
May 31, 2017
AbbVie Inc at Boston Biotech Boston CEO Conference
May 22, 2017
AbbVie Inc at UBS Global Healthcare Conference - Webcast
May 16, 2017
AbbVie Inc at Informa PLC's Adam Smith Russian Pharmaceutical Conference
May 5, 2017
AbbVie Inc Annual Shareholders Meeting
May 3, 2017
AbbVie Inc at Deutsche Bank Health Care Conference - Webcast
Apr 27, 2017
Q1 2017 AbbVie Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 26.17% 23.22%
Operating margin 37.00% 36.60%
EBITD margin - 42.09%
Return on average assets 10.42% 9.99%
Return on average equity 142.47% 138.75%
Employees 30,000 -
CDP Score - A-

Address

1 N Waukegan Rd
NORTH CHICAGO, IL 60064-1802
United States - Map
+1-847-9327900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Officers and directors

Richard A. Gonzalez Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
William J. Chase Executive Vice President, Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Michael Severino M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Laura J. Schumacher Executive Vice President, External Affairs, General Counsel and Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Carlos Alban Executive Vice President - Commercial Operations
Age: 54
Bio & Compensation  - Reuters
Henry O. Gosebruch Executive Vice President, Chief Strategy Officer
Age: 44
Bio & Compensation  - Reuters
Timothy J. Richmond Senior Vice President - Human Resources
Age: 50
Bio & Compensation  - Reuters
Azita Saleki-Gerhardt Ph.D. Senior Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Robert A. Michael Vice President, Controller
Age: 46
Bio & Compensation  - Reuters
Robert J. Alpern M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters